+++ Einfach investieren ? mit Kapitalschutz oder Teilschutz ? raiffeisenzertifikate.at ? jetzt in Zeichnung +++ -W-
07.08.2013 14:00:00

Services Sector Announces Monthly Sales Results, Dividends, New Products, Agreements and Appointments - Research Report on Target, CVS, COSTCO, Rite Aid, and GNC

NEW YORK, August 7, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Target Corp. (NYSE: TGT), CVS Caremark Corporation (NYSE: CVS), Costco Wholesale Corporation (NASDAQ: COST), Rite Aid Corp. (NYSE: RAD), and GNC Holdings Inc. (NYSE: GNC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Target Corp. Research Report

On August 1, 2013, Target Corp. (Target) introduced the new Sonia Kashuk Bath & Body Collection. Target informed that the new Bath & Body collection joins Sonia Kashuk's luxury line of makeup and accessories. According to the Company, the 24 new products are brought to life with four exquisite fragrances created in collaboration by Sonia and perfumer extraordinaire, Jérôme Epinette of Robertet. Further, Target stated that each of the fragrance, Innocencia, Purple Seductia, Yellow Alluriana and Red Promisia, is custom-made from the finest ingredients and are designed in partnership by Sonia and the creative boutique agency Buero New York. The Full Research Report on Target Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/TGT]

--

CVS Caremark Corporation Research Report

On August 2, 2013, CVS Caremark Corporation (CVS) confirmed an agreement in principle with the staff of the Boston Regional Office of the Securities and Exchange Commission (SEC) to resolve an investigation by the SEC of certain events that occurred in the year 2009. CVS informed that this investigation focuses on events that occurred in Q3 2009 and Q4 2009, including certain public disclosures made by CVS, transactions in the Company's securities by certain current and former employees, and certain aspects of the purchase accounting adjustment related to the October 2008 Longs Drug Stores acquisition. According to the Company, the agreement in principle was reached following extensive discussions with the SEC over the last several months and the settlement remains subject to completion of final documentation and approval by the Commission and federal court. CVS also reported that under the terms of the agreement in principle, it will pay a $20 million civil penalty, which has been fully reserved in CVS' financial statements and will not require CVS Caremark to restate its earnings for any reporting period. The Full Research Report on CVS Caremark Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/CVS]

--

Costco Wholesale Corporation Research Report

On July 21, 2013, Costco Wholesale Corporation's (COSTCO) Board of Directors declared a quarterly cash dividend on Costco common stock of $0.31 per share. COSTCO reported that the quarterly dividend will be payable on August 23, 2013, to shareholders of record at the close of business on August 9, 2013. The Full Research Report on Costco Wholesale Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/COST]

--

Rite Aid Corp. Research Report

On August 1, 2013, Rite Aid Corp. (Rite Aid) reported its sales results for the month of July 2013 (four weeks period ended July 27, 2013). The Company's same store sales increased 1.3% YoY, while front-end same store sales increased 0.7% YoY in July 2013. Pharmacy same store sales, which included a negative impact from new generic introductions of approximately 307 bps, increased 1.6% YoY and prescription count at comparable stores increased 0.4% YoY. On a year-to-date basis (21-week period ended July 27, 2013), same store sales decreased 1.2% YoY; front-end same store sales increased 0.4% YoY; pharmacy same store sales decreased 1.9% YoY, prescription count at comparable stores was flat year-on-year; and total drugstore sales decreased 1.5% YoY to $10.1 billion. The Full Research Report on Rite Aid Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/RAD]

 -

GNC Holdings Inc. Research Report

On July 29, 2013, GNC Holdings Inc. (GNC) announced the appointment of Carmine Fortino as Executive Vice President for Business Development. Commenting on the appointment, Joseph Fortunato, GNC's Chairman, President, and CEO, said, "Carmine is a great addition to the GNC senior management team. His background in multi-channel development across the health & wellness segment will enhance our approach to new market opportunities as we continue to implement GNC's proven growth strategy." The Full Research Report on GNC Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/GNC]

----

EDITOR NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  • For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

  • COMPLIANCE PROCEDURE

    Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

    NOT FINANCIAL ADVICE

    Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

    NO WARRANTY OR LIABILITY ASSUMED

    Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


    SOURCE Investors' Reports

    Analysen zu Target Corp.mehr Analysen

    Eintrag hinzufügen
    Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
    Es ist ein Fehler aufgetreten!

    Aktien in diesem Artikel

    Costco Wholesale Corp. 921,30 -0,16% Costco Wholesale Corp.
    CVS Health Corp 55,53 0,85% CVS Health Corp
    Target Corp. 123,34 3,04% Target Corp.